A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update

被引：26

作者：

Rha, Sun Young ^{[1
]}

Lee, Choong-kun ^{[2
]}

Kim, Hyo Song ^{[2
]}

Kang, Beodeul ^{[3
]}

Jung, Minkyu ^{[4
]}

Kwon, Woo Sun ^{[5
]}

Bae, Woo Kyun ^{[6
]}

Koo, Dong-Hoe ^{[7
]}

Shin, Su-Jin ^{[8
]}

Jeung, Hei-Cheul ^{[9
]}

Zang, Dae Young ^{[10
]}

Chung, Hyun Cheol ^{[2
]}

机构：

[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea

[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Seoul, South Korea

[4] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[5] Song Dang Inst Canc Res, Seoul, South Korea

[6] Chonnam Natl Univ, Sch Med, Gwangju, South Korea

[7] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Hematol & Med Oncol,Dept Internal Med, Seoul, South Korea

[8] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea

[9] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea

[10] Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang Si, South Korea

来源：

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.218

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

218

引用

页数：3